Keisuke Futamura, Tetsunari Hase, Akihito Tanaka, Yoshinori Sakai, Shotaro Okachi, Hirofumi Shibata, Futoshi Ushijima, Takahiko Hashimoto, Kuniya Nakashima, Katsuki Ito, Takanori Yamamoto, Atsushi Numaguchi, Yasuya Inden, Makoto Ishii
Entrectinib, a multikinase inhibitor of ROS1 and tropomyosin receptor kinases, is recommended to treat ROS1 -positive metastatic non-small cell lung cancer (NSCLC). In a previous study, entrectinib-related cardiotoxicity occurred in 2% of patients; however, lethal arrhythmias remain understudied. We encountered a case of fatal arrhythmia due to drug-induced Brugada syndrome caused by entrectinib. An 81-year-old Japanese male with lung adenocarcinoma harboring ROS1 -fusion gene was treated with entrectinib. The patient developed lethal arrhythmias three days after drug initiation, including ventricular tachycardia with Brugada-like electrocardiogram changes...
October 2023: International cancer conference journal